These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33397150)

  • 1. An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases.
    Filgueira LM; Cervantes JB; Lovelle OA; Herrera C; Figueredo C; Caballero JA; Sánchez N; Berrio J; Lorenzo G; Cepeda M; Ramos M; Saavedra D; Añe-Kouri AL; Mazorra Z; Leon K; Crombet T; Caballero A
    Immunotherapy; 2021 Mar; 13(4):289-295. PubMed ID: 33397150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications.
    Loganathan S; Athalye SN; Joshi SR
    Expert Opin Biol Ther; 2020 Sep; 20(9):1025-1031. PubMed ID: 32700604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19.
    Díaz Y; Ramos-Suzarte M; Martín Y; Calderón NA; Santiago W; Viñet O; La O Y; Oyarzábal JPA; Pérez Y; Lorenzo G; Cepeda M; Saavedra D; Mazorra Z; Estevez D; Lorenzo-Luaces P; Valenzuela C; Caballero A; Leon K; Crombet T; Hidalgo CJ
    Gerontology; 2020; 66(6):553-561. PubMed ID: 33105142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab.
    Aira LE; López-Requena A; Fuentes D; Sánchez L; Pérez T; Urquiza A; Bautista H; Falcón L; Hernández P; Mazorra Z
    MAbs; 2014; 6(3):783-93. PubMed ID: 24594862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis.
    Dogra S; Uprety S; Suresh SH
    Expert Opin Biol Ther; 2017 Mar; 17(3):395-402. PubMed ID: 28064543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Itolizumab Treatment for Cytokine Release Syndrome in Moderate to Severe Acute Respiratory Distress Syndrome Due to COVID-19: Clinical Outcomes, A Retrospective Study.
    Gore V; Kshirsagar DP; Bhat SM; Khatib KI; Mansukhani B
    J Assoc Physicians India; 2021 Feb; 69(2):13-18. PubMed ID: 33527804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy.
    Iovino L; Thur LA; Gnjatic S; Chapuis A; Milano F; Hill JA
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2.
    Corominas H; Castellví I; Diaz-Torné C; Matas L; de la Rosa D; Mangues MA; Moya P; Pomar V; Benito N; Moga E; Sosa NH; Casademont J; Domingo P
    Medicine (Baltimore); 2021 May; 100(19):e25923. PubMed ID: 34106658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19.
    Kumar S; De Souza R; Nadkar M; Guleria R; Trikha A; Joshi SR; Loganathan S; Vaidyanathan S; Marwah A; Athalye SN
    Expert Opin Biol Ther; 2021 May; 21(5):675-686. PubMed ID: 33835886
    [No Abstract]   [Full Text] [Related]  

  • 10. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab).
    Le Dantec C; Alonso R; Fali T; Montero E; Devauchelle V; Saraux A; Pers JO; Renaudineau Y
    Immunol Res; 2013 Jul; 56(2-3):341-7. PubMed ID: 23576060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is IL-6 a key cytokine target for therapy in COVID-19?
    Jones SA; Hunter CA
    Nat Rev Immunol; 2021 Jun; 21(6):337-339. PubMed ID: 33850327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
    Kang S; Tanaka T; Inoue H; Ono C; Hashimoto S; Kioi Y; Matsumoto H; Matsuura H; Matsubara T; Shimizu K; Ogura H; Matsuura Y; Kishimoto T
    Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22351-22356. PubMed ID: 32826331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab prescribing criteria for COVID-19 patients.
    Al-Qaaneh AM; Al-Ghamdi FH
    Hum Vaccin Immunother; 2021 Apr; 17(4):1128. PubMed ID: 33079613
    [No Abstract]   [Full Text] [Related]  

  • 16. The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.
    Rodríguez PC; Prada DM; Moreno E; Aira LE; Molinero C; López AM; Gómez JA; Hernández IM; Martínez JP; Reyes Y; Milera JM; Hernández MV; Torres R; Avila Y; Barrese Y; Viada C; Montero E; Hernández P
    Clin Exp Immunol; 2018 Feb; 191(2):229-239. PubMed ID: 28963724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19.
    Geng J; Wang F; Huang Z; Chen X; Wang Y
    Cytokine; 2021 Jul; 143():155544. PubMed ID: 33926774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality.
    Moradian N; Gouravani M; Salehi MA; Heidari A; Shafeghat M; Hamblin MR; Rezaei N
    Eur Cytokine Netw; 2020 Sep; 31(3):81-93. PubMed ID: 33361013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
    Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
    Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The shortcomings of tocilizumab in COVID-19.
    Tirupathi R; Bharathidasan K; Areti S; Kaur J; Salim S; Al-Tawfiq JA
    Infez Med; 2020 Dec; 28(4):465-468. PubMed ID: 33257619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.